Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Placebo-Controlled, Double-Blind, Adaptive Study to Assess the Safety and Efficacy of Intravenous J147 Combined With Endovascular Therapy in Patients With Acute Ischemic Stroke

NCT07430917 is registered in ClinicalTrials.gov with Abrexa Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07430917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07430917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Placebo-Controlled, Double-Blind, Adaptive Study to Assess the Safety and Efficacy of Intravenous J147 Combined With Endovascular Therapy in Patients With Acute Ischemic Stroke
Lead sponsor
Abrexa Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 22, 2026
Completion date
July 1, 2028
Enrollment
196 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke